JP7312706B2 - 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ - Google Patents

血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ Download PDF

Info

Publication number
JP7312706B2
JP7312706B2 JP2019570882A JP2019570882A JP7312706B2 JP 7312706 B2 JP7312706 B2 JP 7312706B2 JP 2019570882 A JP2019570882 A JP 2019570882A JP 2019570882 A JP2019570882 A JP 2019570882A JP 7312706 B2 JP7312706 B2 JP 7312706B2
Authority
JP
Japan
Prior art keywords
cells
composition
dose
cell
hu5f9
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020525435A (ja
JP2020525435A5 (https=
Inventor
マジェティ，ラビンドラ
ピー． チャオ，マーク
リュウ，ジー
フォルクマー，ジェンス－ピーター
エル． ワイスマン，アービング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2020525435A publication Critical patent/JP2020525435A/ja
Publication of JP2020525435A5 publication Critical patent/JP2020525435A5/ja
Priority to JP2023067723A priority Critical patent/JP2023083424A/ja
Application granted granted Critical
Publication of JP7312706B2 publication Critical patent/JP7312706B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019570882A 2017-06-21 2018-06-21 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ Active JP7312706B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023067723A JP2023083424A (ja) 2017-06-21 2023-04-18 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523182P 2017-06-21 2017-06-21
US62/523,182 2017-06-21
PCT/US2018/038798 WO2018237168A1 (en) 2017-06-21 2018-06-21 Dosing parameters for cd47 targeting therapies to hematologic malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023067723A Division JP2023083424A (ja) 2017-06-21 2023-04-18 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ

Publications (3)

Publication Number Publication Date
JP2020525435A JP2020525435A (ja) 2020-08-27
JP2020525435A5 JP2020525435A5 (https=) 2021-07-29
JP7312706B2 true JP7312706B2 (ja) 2023-07-21

Family

ID=64735831

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019570882A Active JP7312706B2 (ja) 2017-06-21 2018-06-21 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ
JP2023067723A Pending JP2023083424A (ja) 2017-06-21 2023-04-18 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023067723A Pending JP2023083424A (ja) 2017-06-21 2023-04-18 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ

Country Status (12)

Country Link
US (3) US11141480B2 (https=)
EP (2) EP3642242B1 (https=)
JP (2) JP7312706B2 (https=)
KR (1) KR102757177B1 (https=)
CN (2) CN110831974B (https=)
AU (2) AU2018290248B2 (https=)
CA (1) CA3063099A1 (https=)
ES (1) ES2976558T3 (https=)
PL (1) PL3642242T3 (https=)
PT (1) PT3642242T (https=)
SI (1) SI3642242T1 (https=)
WO (1) WO2018237168A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
US11072655B2 (en) * 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
WO2018237168A1 (en) * 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
ES2973832T3 (es) * 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
CN121243368A (zh) * 2019-11-27 2026-01-02 Alx肿瘤生物技术公司 用于治疗癌症的组合疗法
CN111905101B (zh) * 2020-07-03 2022-09-23 中山大学 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法
WO2022007947A1 (zh) * 2020-07-10 2022-01-13 信达生物制药(苏州)有限公司 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
EP4291216A1 (en) * 2021-02-09 2023-12-20 University of Houston System Oncolytic virus for systemic delivery and enhanced anti-tumor activities
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
AU2024225341A1 (en) 2023-02-21 2025-09-04 Osteal Therapeutics, Inc. Methods of treating a localized infection with locally administered antibiotics

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543819T3 (es) 1998-11-09 2015-08-24 Biogen Inc. Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) * 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
CA2771336C (en) * 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
NZ710695A (en) * 2013-02-06 2020-05-29 Inhibrx Inc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
CN112245586A (zh) 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
EP3046627B1 (en) 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
CN103943054B (zh) 2014-01-27 2016-07-13 上海中航光电子有限公司 栅极驱动电路、tft阵列基板、显示面板及显示装置
KR102271434B1 (ko) 2014-09-26 2021-07-01 엘지전자 주식회사 이동단말기 및 그 제어방법
CN113528663A (zh) 2014-12-10 2021-10-22 得克萨斯州大学系统董事会 使用基因组特异性探针的循环肿瘤和肿瘤干细胞检测
WO2017053423A1 (en) * 2015-09-21 2017-03-30 Erasmus University Medical Center Anti-cd47 antibodies and methods of use
WO2018237168A1 (en) 2017-06-21 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Dosing parameters for cd47 targeting therapies to hematologic malignancies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
mAbs, 2010, Vol. 2, Issue 4, pp. 440-448
PLoS ONE, 2015, 10(9), e0137345, pp. 1-23

Also Published As

Publication number Publication date
US20200147212A1 (en) 2020-05-14
PL3642242T3 (pl) 2024-05-27
CN110831974A (zh) 2020-02-21
EP3642242B1 (en) 2024-02-07
JP2023083424A (ja) 2023-06-15
AU2024227248A1 (en) 2024-10-31
US12194093B2 (en) 2025-01-14
EP4368206A2 (en) 2024-05-15
JP2020525435A (ja) 2020-08-27
US12274746B2 (en) 2025-04-15
ES2976558T3 (es) 2024-08-05
CA3063099A1 (en) 2018-12-27
US20210401979A1 (en) 2021-12-30
EP4368206A3 (en) 2024-08-14
CN110831974B (zh) 2024-05-14
AU2018290248A1 (en) 2019-11-28
PT3642242T (pt) 2024-04-16
WO2018237168A1 (en) 2018-12-27
US20230270852A1 (en) 2023-08-31
US11141480B2 (en) 2021-10-12
EP3642242A1 (en) 2020-04-29
SI3642242T1 (sl) 2024-05-31
AU2018290248B2 (en) 2024-08-01
KR102757177B1 (ko) 2025-01-21
EP3642242A4 (en) 2021-06-23
KR20200019619A (ko) 2020-02-24
CN117065013A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
JP7312706B2 (ja) 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ
JP7494245B2 (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
KR102416144B1 (ko) 환자에서 항-cd19 치료법의 치료 이익의 예측 방법
HK40114200A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
US20220119523A1 (en) Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway
HK40103499A (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
HK40025478A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40025478B (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40023801A (en) Dosing parameters for cd47 targeting therapies to hematologic malignancies
HK40023801B (zh) 针对血液恶性肿瘤的cd47靶向疗法的给药参数
Navarrete-Sirvent Nk cells as biomarkers of response to antiegfr therapy in metastatic colorectal cancer: clinical implications and therapeutic opportunities
HK40002753B (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20200217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20221207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221207

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20221227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230707

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230710

R150 Certificate of patent or registration of utility model

Ref document number: 7312706

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350